C5 and anti-neutrophil cytoplasmic antibody-associated vasculitis: Studies have shown promising results for C3 inhibition with pegcetacoplan in C3G patients, Factor B inhibition with Iptacopan in IgAN patients, and C5a inhibition with Avacopan in AAV.